Moderna Genomics: the start-up–like unit leveraging RNA for gene editing

Separate from its pipeline of RNA vaccines and therapies, Moderna is building a semi-autonomous unit tasked with developing the company’s signature modality as a vehicle for gene editing machinery.

The “lofty but reachable goal” of the Moderna Genomics unit at  Moderna Inc. (NASDAQ:MRNA) is to treat “everyone with monogenic liver diseases” via platforms conducive to n-of-one therapies, said Eric Huang, the division’s general manager and CSO. “All the pieces are there,” he told BioCentury...